62. (1) The alternative requirements that must be satisfied in order for a person to be eligible for funding under clause 85.7 (4) (b) of the Health Professions Procedural Code are prescribed in this section. O. Reg. 225/13, s. 1. (2) A person is eligible for funding for therapy or counselling if, (a)  there is an admission made by a member in a statement to the College or in an agreement with the College that he or she sexually abused the person while the person was a patient of the member; (b)  a member has been found guilty under the Criminal Code (Canada) of sexually assaulting the person while the person was a patient of the member; (c)  there is a statement, contained in the written reasons of a committee of the College given after a hearing, that the person, while a patient, was sexually abused by a member; or (d)  there is sufficient evidence presented to the Patient Relations Committee to support a reasonable belief that the person, while a patient, was sexually abused by a member. O. Reg. 225/13, s. 1. (3) For the purposes of clause (2) (d), and without limiting the generality of that clause, the following kinds of evidence may support a reasonable belief that a person, while a patient, was sexually abused by a member: 1.  Evidence of reports made with respect to the member under subsection 85.1 (1) or 85.2 (1) of the Health Professions Procedural Code. 2.  Evidence that corroborates the person’s allegations of sexual abuse by the member. O. Reg. 225/13, s. 1. (4) A person is not eligible under subsection (2) unless, at the time the sexual abuse occurred, the person was a patient of the member and the member was practising in Ontario. O. Reg. 225/13, s. 1. (5) Despite subsections (2), (3) and (4), a person is eligible for funding for therapy or counselling under this Part only if, (a)  the person submits an application for funding to the Patient Relations Committee in the form provided by the College and, in the application, the person names the member who is alleged to have sexually abused the person; (b)  the person adheres to the procedures followed by the Patient Relations Committee when determining whether the person has satisfied the requirements for eligibility for funding; and (c)  the person provides such other information as is required by the Patient Relations Committee. O. Reg. 225/13, s. 1. (6) A decision by the Patient Relations Committee that a person is eligible for funding for therapy or counselling does not constitute a finding against the member and shall not be considered by any other committee of the College dealing with the member. O. Reg. 225/13, s. 1. Tables 1, 2 Revoked: O. Reg. 452/16, s. 2. Schedule 1   Injected Substances Analgesics and Antipyretics Codeine — For patient education and demonstration only Hydromorphone — For patient education and demonstration only Morphine — For patient education and demonstration only Nalbuphine — For patient education and demonstration only Antibacterials Amikacin Ampicillin Cefazolin Cefepime Cefotaxime Cefoxitin Ceftazidime Ceftriaxone Clindamycin Cloxacillin Ertapenem Gentamicin Penicillin G Anticholinergic Agents Scopolamine — Must not be administered intravenously Hyoscine — Must not be administered intravenously Glycopyrrolate — Must not be administered intravenously Anticoagulants Dalteparin — Must not be administered intravenously Danaparoid — Must not be administered intravenously Enoxaparin — Must not be administered intravenously Fondaparinux — Must not be administered intravenously Heparin — For patient education and demonstration only Nadroparin — Must not be administered intravenously Tinazaparin Antidiabetic Agents Exenatide Insulins Liraglutide Dulaglutide Lixisenatide Semaglutide Antihemorrhagic Agents Emicizumab Antihistamines Diphenhydramine — Only for monitoring and management of allergic reactions Dimenhydrinate — Must not be administered intravenously Antimigraine Agents Sumatriptan Erenumab Antiparkinsonian Agents Apomorphine Benztropine Antivirals Enfuvirtide Interferons Peginterferon alfa-2a Central Nervous System Agents, Miscellaneous Inotersen Complement Inhibitors Icatibant Lanadelumab Disease-modifying Antirheumatic Drugs Abatacept Adalimumab Anakinra Etanercept Golimumab — Must not be administered intravenously Ustekinumab — Must not be administered intravenously Methotrexate — Must not be administered intravenously Sarilumab Tocilizumab — Must not be administered intravenously Enzymes Asfotase Alfa GI Drugs, Miscellaneous Certolizumab Pegol Methylnaltrexone Gonadotropins and Antigonadotropins Follitropin-alpha Follitropin-beta Follitropin-delta Gonadotropin-chorionic Gonadotropin-chorionic-alfa Lutropin-alfa Menotropins Goserelin — For patient education and demonstration only Triptorelin acetate Gonadotropin-releasing Hormone Antagonists Cetrorelix Ganirelix Heavy Metal Antagonists Deferoxamine — For patient education and demonstration only Hematopoietic Agents Darbepoetin alfa — Must not be administered intravenously Epoetin alfa — Must not be administered intravenously Filgrastim — Must not be administered intravenously Pegfilgrastim Romiplostim — For patient education and demonstration only Immunomodulatory Agents Denosumab Glatiramer Interferon-Beta-1A Interferon-Beta-1B Natalizumab Immunosuppressive Agents Belimumab — Must not be administered intravenously Mepolizumab Miscellaneous Agents Sterile Water for Injection (Diluent) Sodium Chloride Parathyroid Calcitonin Salmon — For patient education and demonstration only Teriparatide Pituitary Desmopressin — For patient education and demonstration only Vasopressin — For patient education and demonstration only Progestins Medroxyprogesterone Progesterone Prokinetic Agents Metoclopramide Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) Inhibitors Alirocumab Evolocuma Psychotherapeutic Agents Haloperidol — For patient education and demonstration only Methotrimeprazine — For patient education and demonstration only Respiratory Tract Agents Omalizumab Skin And Mucous Membrane Agents Brodalumab Dupilumab Guselkumab Ixekizumab Risankizumab — Must not be administered intravenously Secukinumab Somatostatin Agonists and Antagonists Pasireotide Octreotide — Must not be administered intravenously Lanreotide Somatotropin Agonists and Antagonists Somatropin Pegvisomant Tesamorelin Sympatholytic (Adrenergic Blocking) Agents Dihydroergotamine — Must not be administered intravenously Vitamins Cyanocobalamin Folic Acid — Must not be administered intravenously Pyridoxine — Must not be administered intravenously Thiamine — Must not be administered intravenously Ascorbic Acid — Must not be administered intravenously Vitamin K O. Reg. 95/23, s. 2. Schedule 2   Inhaled Substances Anticholinergic Agents Ipratropium Tiotropium Aclidinium Glycopyrronium Umeclidinium Formoterol Indacaterol Olodaterol Salbutamol Salmeterol Terbutaline Vilanterol Anti-infective Agents Zanamivir Levofloxacin Tobramycin Aztreonam Autonomic Drugs, Miscellaneous Nicotine Eye, Ear, Nose and Throat (EENT) Preparations Sodium Cromoglycate Beclomethasone Budesonide Ciclesonide Fluticasone Mometasone Miscellaneous Agents Sodium chloride Sterile water for inhalation Respiratory Tract Agents Acetylcysteine Dornase alfa O. Reg. 95/23, s. 2. Schedule 3   Vaccines 1.  Bacille Calmette-Guerin (BCG) Vaccines 2.  Haemophilus Influenzae type b (Hib) Vaccines 3.  Meningococcal Vaccines 4.  Pneumococcal Vaccines 5.  Typhoid Vaccines 6.  Combined Typhoid and Hepatitis A Vaccines 7.  Hepatitis A Vaccines 8.  Hepatitis B Vaccines 9.  Hepatitis A and B combined Vaccines 10.  Herpes Zoster Vaccines 11.  Human Papillomavirus (HPV) Vaccines 12.  Japanese Encephalitis Vaccines 13.  Rabies Vaccines 14.  Varicella Vaccines 15.  Yellow Fever Vaccines O. Reg. 452/16, s. 3. Schedule 4   DrugS — Minor Ailments Item   Column 1   Minor Ailment   Column 2   Drug Classes   Column 3   Specified Drugs 

  1.   Acne (mild)   Skin and Mucous Membrane Agents   Adapalene Azelaic acid Benzoyl peroxide Clindamycin Dapsone Erythromycin Glycolic acid Salicylic acid Tazarotene Tretinoin Trifarotene 

  2a.   Allergic rhinitis   Antihistamines     Azelastine Bilastine Cetirizine Cyproheptadine Desloratadine Fexofenadine Loratadine Olopatadine Rupatadine 

  2b.   Allergic rhinitis   Corticosteroids     Beclomethasone Budesonide Ciclesonide Fluticasone Mometasone Triamcinolone 

  3.   Candidal stomatitis   Antifungals     Nystatin 

  4a.   Conjunctivitis (bacterial, allergic or viral)   Antiallergic Agents     Antazoline Bepotastine Cromolyn sodium (Sodium cromoglycate) Ketotifen Lodoxamide Olopatadine Pheniramine 

  4b.   Conjunctivitis (bacterial, allergic or viral)   Antibacterials     Erythromycin Fusidic acid Gramicidin Polymyxin B Tobramycin Trimethoprim 

  4c.   Conjunctivitis (bacterial, allergic or viral)   Vasoconstrictors     Naphazoline Oxymetazoline Phenylephrine Tetrahydrozoline 

  5.   Dermatitis (atopic/eczema, allergic or contact)   Anti-inflammatory Agents     Beclomethasone Betamethasone valerate Clobetasone Crisaborole Desonide Fluocinolone Hydrocortisone Prednicarbate Triamcinolone 

  6a.   Dermatitis (diaper)   Antifungals     Ciclopirox Clotrimazole Ketoconazole Miconazole Nystatin  

  6b.   Dermatitis (diaper)   Anti-inflammatory Agents     Desonide Hydrocortisone 

  7.   Dysmenorrhea   Nonsteroidal Anti-inflammatory Agents     Acetylsalicylic acid (ASA) Celecoxib Diclofenac Flurbiprofen Ibuprofen Ketoprofen Mefenamic acid Naproxen 

  8a.   Gastroesophageal reflux disease (GERD)   Antacids and Adsorbents     Alginic acid Aluminum hydroxide Calcium carbonate Magnesium salts 

  8b.   Gastroesophageal reflux disease (GERD)   Histamine H2-Antagonists     Cimetidine Famotidine Nizatidine Ranitidine  

  8c.   Gastroesophageal reflux disease (GERD)   Proton-Pump Inhibitors     Dexlansoprazole Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole 

  9.   Hemorrhoids   Skin and Mucous Membrane Agents     Dibucaine (Cinchocaine) Esculin (Aesculin) Framycetin (Neomycin B) Hydrocortisone Phenylephrine Pramoxine Zinc sulfate 

  10a.   Herpes labialis   Anti-inflammatory Agents     Hydrocortisone 

  10b.   Herpes labialis   Antivirals     Acyclovir Docosanol Famciclovir Valacyclovir 

  11.   Impetigo   Antibacterials     Bacitracin Fusidic acid (Sodium fusidate) Gramicidin Mupirocin Ozenoxacin Polymyxin B 

  12a.   Insect bites and urticaria   Antihistamines     Bilastine Cetirizine Chlorpheniramine Cyproheptadine Desloratadine Diphenhydramine Fexofenadine Hydroxyzine Loratadine Rupatadine 

  12b.   Insect bites and urticaria   Antipruritics and Anti-inflammatory Agents     Benzocaine Calamine Camphor Desonide Hydrocortisone Lidocaine Menthol Pramoxine Zinc oxide 

  13a.   Musculoskeletal sprains and strains   Analgesics     Acetaminophen   

  13b.   Musculoskeletal sprains and strains   Nonsteroidal Anti-inflammatory Agents     Acetylsalicylic acid (ASA) Celecoxib Diclofenac Flurbiprofen Ibuprofen Ketoprofen Mefenamic acid Naproxen 

  14.   Nausea and vomiting of pregnancy   Antiemetics and Antinauseants     Dimenhydrinate Diphenhydramine Doxylamine Promethazine Pyridoxine 

  15.   Oral aphthae   Anti-inflammatory Agents     Triamcinolone 

  16.   Pinworms/Threadworms   Anthelmintics     Mebendazole Pyrantel pamoate 

  17.   Tick bites, post-exposure prophylaxis to prevent Lyme disease   Antibacterials     Doxycycline 

  18.   Urinary tract infection (uncomplicated)   Urinary Anti-infectives     Fosfomycin Nitrofurantoin Sulfamethoxazole Trimethoprim 

  19.   Vulvovaginal candidiasis   Antifungals     Clotrimazole Fluconazole Miconazole Terconazole O. Reg. 179/23, s. 2.